Vanderbilt-Ingram website >
Vanderbilt researchers are studying a potential therapy for acute myeloid leukemia that targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.
During the past year, multiple new appointments and additions strengthened VUMC’s core missions.
The American Urological Association has announced that Vanderbilt’s Sam S. Chang, MD, MBA, is one of its 2024 award recipients.
A group of Ukrainian oncologists recently visited Vanderbilt-Ingram Cancer Center where they toured research labs, observed tumor board meetings, met with several Vanderbilt oncologists, and attended the 23rd Annual Retreat for Cancer Biology.